Innovation
Ubicació i contacte
Agenda
Collaborate

INIM. Infection and immunity

HEALTH AND THE ENVIRONMENT
SEPSIS MALALTIES INFECCIOSES TOXICOLOGIA MICROBIOLOGIA
TARGETS

INIM is a research group specializing in the study of infectious diseases, and its main activity is the study of the immunopathogenesis of HIV, a complex and multifactorial phenomenon that affects the normal function of the immune system.

RESPONSIBLE

  • Francesc Vidal Marsal

  • PRESENTATION
  • RESEARCH LINES
  • Transfer
  • Publications
  • Projects
  • Contact

The group that was created in 1993 by Professor Francesc Vidal (principal investigator) has the presence of clinical and basic researchers who have focused their research on studying the pathophysiological pathways potentially involved in HIV infection and the body’s response to antiretroviral treatment. In fact, in recent years, the group has made a great effort to become a national and international benchmark in the search for biomarkers predictive and potential therapeutic targets through the approach through omic sciences (genomics, proteomics, transcriptomic and metabolomics).

All efforts in the field of HIV / AIDS research have been recognized by the AIDS Research Network (RETICS-RIS) of the Carlos III Health Research Institute (ISCIII), which has funded the group uninterruptedly since 2003 and by the Agency for the Management of University and Research Grants (AGAUR) of the Generalitat de Catalunya.

INIM has prioritized its research in the study of two very well-defined subgroups of HIV-infected patients, non-recovering HIV individuals and those we define as elite controllers. Non-recoverers are infected subjects who, although they achieve virological suppression when treated with antiretrovirals, do not achieve complete immune recovery, presenting a worse prognosis over time compared to recoverers. Elite controllers are infected subjects who do not need to be treated with antiretrovirals because their body is able to control the virus, in some cases over a long period of time, and therefore could be key to achieving a functional cure.

  1. Immunogenetics and immunopathogenesis of HIV infection
  2. Pharmacogenetics and toxicogenetics of antiretroviral treatment (ART)
  3. Epidemiological and clinical studies of HIV infection
  4. Innovation in ART

  • Patents:

    Títol: Methods for the prognosis of HIV-Infected subjects

    Referència: EP18382669.2 – PCT/EP2019/074906

    Autors: Rodriguez Gallego, Esther; Rull Aixa, Anna; Peraire Forner, Joaquim; Viladés Laborda, Consuelo; Vidal Marsal, Francesc; Alba Elvira, Veronica; Ruiz-Mateos Carmona, Eziquiel; López Cortés, Luis Fernando; Tarancón Díez, Laura

  • Guies clíniques

    Mensa J; Soriano A; García-Sánchez JE; Letang E; López-Suñé E; Marco F, Llinares P. Guía de Terapéutica Antimicrobiana 2019. (Spain): Antares Editorial, 2019. ISBN-13: 9788488825292

  • Mensa J; Gatell JM; García-Sánchez JE; Letang E; López-Suñé E; Marco F. Guía de Terapéutica Antimicrobiana 2018. (Spain): Antares Editorial, 2018. ISSN-e 2255-0569

  • Gatell JM; Clotet B; Podzamczer D; Miró J; Mallolas J. Guía Práctica del Sida: clínica, diagnóstico y tratamiento 2017. (Spain). Antares Editorial, 2016. ISBN 978-84-88825-22-3

  • Gatell JM; Clotet B; Podzamczer D; Miró J; Mallolas J. Guía Práctica del Sida: clínica, diagnóstico y tratamiento 2016. (Spain). Antares Editorial, 2015. ISBN 978-84-88825-17-9

  • Mensa J; Gatell JM; García-Sánchez JE; Letang E; López-Suñé E; Marco F. Guía de Terapéutica Antimicrobiana. (Spain): Antares Editorial, 2014. ISBN 978-84-88825-15-5

  • Mensa J; Gatell JM; García-Sánchez JE; Letang E; López-Suñé E; Marco FGuía de Terapéutica Antimicrobiana. (Spain): Antares Editorial, 2014. ISBN 978-84-88825-13-1

    Year

    Drug-druginteractions when treating HIV-related metabolic disorders

    Gutierrez MDM, Mateo MG, Corbacho N, Vidal F, Domingo P

    Expert Opin DrugMetab Toxicol

    DOI: 10.1080/17425255.2019.1667334

    Does choice of antiretroviraldrugs matter for inflammation?

    Gutierrez MDM, Mateo MG, Vidal F, Domingo P

    Expert Rev Clin Pharmacol

    DOI: 10.1080/17512433.2019.1605902

    Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.

    Llibre JM, Montoliu A, Miró JM, Domingo P, Riera M, Tiraboschi J, Curran A, Homar F, Ambrosioni J, Abdulghani N, Force L, Peraire J, Casabona J; PISCIS Cohort group

    HIV Med

    DOI: 10.1111/hiv.12710

    Patients With Systemic LupusErythematosus Show an Increased Arterial Stiffness That is Predicted by IgMAnti-β(2) -Glycoprotein I and Small Dense High-Density Lipoprotein Particles

    187: Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigó N, Català A,Benavent M, Garcés E, Navarro A, Castro A

    Arthritis Care Res (Hoboken)

    DOI: 10.1002/acr.23594

    Microbiological contamination of conventional andreclaimed irrigation water: Evaluation and management measures

    201: Rusiñol M, Hundesa A, Cárdenas-Youngs Y, Fernández-Bravo A, Pérez-CataluñaA, Moreno-Mesonero L, Moreno Y, Calvo M, Alonso JL, Figueras MJ, Araujo R,Bofill-Mas S, Girones R

    Sci TotalEnviron

    DOI: 10.1016/j.scitotenv.2019.136298

    The MetallochaperoneEncoding Gene hypA Is Widely Distributed among Pathogenic Aeromonas spp and Its Expression Is Increased under Acidic pH and within Macrophages

    232: Fernández-Bravo A, López-Fernández L, Figueras MJ

    Microorganisms

    DOI: 10.3390/microorganisms7100415

    Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among reatment-experienced patients in clinical practice: a multicentre cohort study

    Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    AIDS Res Ther. 2020 Jul 20;17(1):45.
    DOI: 10.1186/s12981-020-00302-2

    Lack of Association of Initial Viral Load in SARS-CoV-2 Patients with In-Hospital Mortality

    Carrasquer A, Peiró ÓM, Sanchez-Gimenez R, Lal-Trehan N, Del-Moral-Ronda V, Bonet G, Gutierrez C, Fort-Gallifa I, Martin-Grau C, Benavent C, Vidal F, Bardají A.
    Am J Trop Med Hyg. 2020 Dec 23;104(2):540–5.
    DOI: 10.4269/ajtmh.20-1427

    Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry)

    Solans-Laqué R, Rodriguez-Carballeira M, Rios-Blanco JJ, Fraile G, Sáez-Comet L, Martinez-Zapico A, Frutos B, Solanich X, Fonseca-Aizpuru E, Pasquau-Liaño F, Zamora M, Oristrell J, Fanlo P, Lopez-Dupla M, Abdilla M, García-Sánchez I, Sopeña B, Castillo MJ, Perales I, Callejas JL.
    Arthritis Care Res (Hoboken). 2020 Jul;72(7):1001-1010.
    DOI: 10.1002/acr.23912

    High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients

    Yeregui E, Viladés C, Domingo P, Ceausu A, Pacheco YM, Veloso S, Inciarte A, Vidal-González J, Peraire M, Perpiñán C, Falcó V, Masip J, Alba V, Vargas M, Martí A, Reverté L, Mallolas J, Vidal F, Peraire J, Rull A.
    EBioMedicine. 2020 Dec;62:103077.
    DOI: 10.1016/j.ebiom.2020.103077

    Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects

    Rosado-Sánchez I, De Pablo-Bernal R, Rull A, Gónzalez J, Moreno S, Vinuesa D, Estrada V, Muñoz-Fernández MÁ, Vidal F, Leal M, Pacheco YM.
    Front Immunol. 2020 Nov 6;11:581307.
    DOI: 10.3389/fimmu.2020.581307

    The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    Guerrero-Beltrán C, Martínez-Sanz J, Álvarez M, Olalla J, García-Álvarez M, Iribarren JA, Masiá M, Montero M, García-Bujalance S, Blanco JR, Rivero M, García-Fraile LJ, Espinosa N, Rodríguez C, Aguilera A, Vidal-Ampurdanes MC, Martínez M, Iborra A, Imaz A, Gómez-Sirvent JL, Peraire J, Portilla J, Caballero E, Alejos B, García F, Moreno S; CoRIS.
    J Antimicrob Chemother. 2020 May 1;75(5):1294-1300.
    DOI: 10.1093/jac/dkaa009

     

    Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial

    Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, Burgos J, Falcó V, Ribera E, Torrella A, Planas B, Peraire J, Crespo M.
    J Clin Med. 2020 Apr 25;9(5):1246.
    DOI: 10.3390/jcm9051246

    New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144

    Hernández-Walias F, Ruiz-de-León MJ, Rosado-Sánchez I, Vázquez E, Leal M, Moreno S, Vidal F, Blanco J, Pacheco YM, Vallejo A.
    Sci Rep. 2020 Feb 19;10(1):2937.
    DOI: 10.1038/s41598-020-60073-8

    Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

    Rivas-Urbina A, Rull A, Aldana-Ramos J, Santos D, Puig N, Farre-Cabrerizo N, Benitez S, Perez A, de Gonzalo-Calvo D, Escola-Gil JC, Julve J, Ordoñez-Llanos J, Sanchez-Quesada JL.
    Biomolecules. 2020 May 29;10(6):829.
    DOI: 10.3390/biom10060829

    Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies

    Acar-Denizli N, Horváth IF, Mandl T, Priori R, Vissink A, Hernandez-Molina G, Armagan B, Praprotnik S, Sebastian A, Bartoloni E, Rischmueller M, Pasoto SG, Nordmark G, Nakamura H, Fernandes Moça Trevisani V, Retamozo S, Carsons SE, Maure-Noia B, Sánchez-Berná I, López-Dupla M, Fonseca-Aizpuru E, Melchor Díaz S, Vázquez M, Díaz Cuiza PE, de Miguel Campo B, Ng WF, Rasmussen A, Dong X, Li X, Baldini C, Seror R, Gottenberg JE, Kruize AA, Sandhya P, Gandolfo S, Kwok SK, Kvarnstrom M, Solans R, Sene D, Suzuki Y, Isenberg DA, Valim V, Hofauer B, Giacomelli R, Devauchelle-Pensec V, Atzeni F, Gheita TA, Morel J, Izzo R, Kalyoncu U, Szántó A, Olsson P, Bootsma H, Ramos-Casals M, Kostov B, Brito-Zerón P.
    Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):85-94. Epub 2020 Oct 22. PMID: 33095152.

    Acute upper limb bilateral ischaemia and tranverse myelitis in a patient with giant cell arteritis

    Yeregui Etxeberia E, Rojas Sánchez RA, Lopez Dupla M.
    2020 Aug 20 [Epub ahead of print] Med Clin (Barc).
    DOI: 10.1016/j.medcli.2020.04.054

    Durability of first-line antiretroviral regimens in the era of integraseinhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015

    Jarrin I, Suarez-Garcia I, Moreno C, Tasias M, Del Romero J, Palacios R,Peraire J, Gorgolas M, Moreno S; Cohort of the Spanish HIV/AIDS Research Network (CoRIS)

    AntivirTher

    DOI: 10.3851/IMP3297

    Proteomic Profile Associated With Loss of Spontaneous HumanImmunodeficiency Virus Type 1 Elite Control

    Rodríguez-Gallego E, Tarancón-Diez L, García F, Del Romero J, Benito JM,Alba V, Herrero P, Rull A, Dominguez-Molina B, Martinez-Madrid O, Martin-Pena L, Pulido F, León A, Rodríguez C, Rallón N, Peraire J, Viladés C, Leal M, Vidal F,Ruiz-Mateos E; HIV-1 Elite Controllers Study Group (ECRIS), Spanish AIDS ResearchNetwork

    J Infect Dis

    DOI: 10.1093/infdis/jiy599

    IL-7/IL-7R genevariants impact circulating IL-7/IL-7R homeostasis and ART-associated immunerecovery status

    Ceausu A, Rodríguez-Gallego E, Peraire J, López-Dupla M, Domingo P, Viladés C, Vidal-Gonzalez J, Peraire M, Perpiñán C, Pacheco YM, Veloso S, Alba V, Vargas M, Castellano AJ, Ruiz-Mateos E, Mallolas J, Vidal F, Rull A

    Sci Rep

    DOI: 10.1038/s41598-019-52025-8

    CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients

    Vitallé J, Terrén I, Orrantia A, Pérez-Garay R, Vidal F, Iribarren JA,Rodríguez C, Lirola AML, Bernal E, Zenarruzabeitia O, Borrego F

    Cell MolImmunol

    DOI: 10.1038/s41423-019-0275-4

    Evolving understanding ofcardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers A study of the Spanish CoRIS cohort,2004-2015

    Masiá M, Padilla S, García JA, García-Abellán J, Fernández M, Bernardino I, Montero M, Peraire J, Pernas B, Gutiérrez F

    PLoS One

    DOI: 10.1371/journal.pone.0215507

    Glutaminolysis and lipoproteins are keyfactors in late immune recovery in successfully treated HIV-infected patients

    Rosado-Sánchez I, Rodríguez-Gallego E, Peraire J, Viladés C, Herrero P,Fanjul F, Gutiérrez F, Bernal E, Pelazas R, Leal M, Veloso S, López-Dupla M,Blanco J, Vidal F, Pacheco YM, Rull A

    Clin Sci (Lond)

    DOI: 10.1042/CS20190111

    Immunometabolism is a key factorfor the persistent spontaneous elite control of HIV-1 infection

    Tarancon-Diez L, Rodríguez-Gallego E, Rull A, Peraire J, Viladés C, PortillaI, Jimenez-Leon MR, Alba V, Herrero P, Leal M, Ruiz-Mateos E, Vidal F; ECRISintegrated in the Spanish AIDS Research Network

    EBioMedicine

    DOI: 10.1016/j.ebiom.2019.03.004

    Surveillance of transmitted drug resistance to integrase inhibitors in Spain:implications for clinical practice

    Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodríguez C,Imaz A, Espinosa N, García-Bujalance S, Pérez-Elías MJ, García-Alvarez M,Iribarren JA, Santos J, Dalmau D, Aguilera A, Vinuesa D, Gutiérrez F, Piérola B, Molina JM, Peraire J, Portilla I, Gómez-Sirvent JL, Olalla J, Galera C, BlancoJR, Riera M, García-Fraile L, Navarro G, Curran A, Poveda E, García F; CoRIS

    J Antimicrob Chemother

    DOI: 10.1093/jac/dkz067

    Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance ofsociodemographic factors

    Teira R, Espinosa N, Gutiérrez MM, Montero M, Martínez E, González F, Lozanode León F, Téllez F, Galindo MJ, Peraire J, Deig E, Muñoz-Sánchez P; para elGrupo de estudio VACH

    Enferm Infecc Microbiol Clin

    DOI: 10.1016/j.eimc.2018.09.008

    Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?

    Rivas-Urbina A, Rull A, Ordóñez-Llanos J, Sánchez-Quesada JL

    Curr Med Chem

    DOI: 10.2174/0929867325666180330093953

    T6SS and ExoA of flesh-eating Aeromonas hydrophila in peritonitis and necrotizing fasciitis during mono- and polymicrobialinfections

    29: Fernández-Bravo A, Kilgore PB, Andersson JA, Blears E, Figueras MJ, Hasan NA,Colwell RR, Sha J, Chopra AK

    Proc Natl Acad Sci U S A

    DOI: 10.3390/microorganisms7100415

    Investigation of the virulence and genomics of Aeromonas salmonicida strains isolated from human patients

    341: Vincent AT, Fernández-Bravo A, Sanchis M, Mayayo E, Figueras MJ, CharetteSJ

    Infect Genet Evol

    DOI: 10.1016/j.meegid.2018.11.019

    Correlation of fatigue with other diseaserelated and psychosocial factors in patients with rheumatoid arthritis treatedwith tocilizumab: ACT-AXIS study

    410: Corominas H, Alegre C, Narváez J, Fernández-Cid CM, Torrente-Segarra V,Gómez MR, Pan FM, Morlà RM, Martínez FJR, Gómez-Centeno A, Ares LL, Molina RG,González-Albo SP, Dalmau-Carolà J, Pérez-García C, Álvarez CB, Ercole L,Terrancle MÁ; ACT-AXIS Study Group

    Medicine (Baltimore)

    DOI: 10.1097/MD.0000000000015947

  • Title: Perfil omico asociado con la progresión de la infección por VIH: en busca de nuevos biomarcadores y de nuevas dianas terapéuticas para lograr la curación funcional del VIH. (PI19/01337)

    Funding entity: Instituto Carlos III

    Duration: 2020-2022

    Principal Investigator: Francesc Vidal Marsal

  • Title: Redes temáticas de investigación cooperativa en salud (RD16/0025/0006)

    Funding entity: Instituto Carlos III

    Duration: 2017-2021

    Principal Investigator: Francesc Vidal Marsal

  • Title: Covid-19 circulating and cellular prognostic biomarkers for Covid-19 progression in patent with SARS-CoV-2 infection using multi omic science.

    Funding entity: Generalitat de Catalunya

    Duration: 2020

    Principal Investigator: Francesc Vidal Marsal

  • Title: Estudio de marcadores ómicos linfocitarios potencialmente predictores de recuperación inmune subóptima en pacientes VIH+ tratados con antiretrovirales. Subestudio de microbiota intestinal. (PI16/00503)

    Funding entity: Instituto Carlos III

    Duration: 2017 – 2020

    Principal Investigator: Francesc Vidal Marsal

  • Title: Gilead fellowship program, transcriptomic and metabolomic study in HIM-infected patents under suppressive antiretroviral treatment who have poor immune recovery.

    Funding entity: Instituto Carlos III

    Duration: 2015 – 2020

    Principal Investigator: Francesc Vidal Marsal

Team Members

Altres grups de Health and the Environment

See all